The effect of central nervous system involvement and irradiation in childhood acute lymphoblastic leukemia: Lessons from the NOPHO ALL-92 and ALL-2000 protocols

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

The effect of central nervous system involvement and irradiation in childhood acute lymphoblastic leukemia : Lessons from the NOPHO ALL-92 and ALL-2000 protocols. / Taskinen, Mervi; Oskarsson, Trausti; Levinsen, Mette; Bottai, Matteo; Hellebostad, Marit; Jonsson, Olafur Gisli; Lähteenmäki, Päivi; Schmiegelow, Kjeld; Heyman, Mats.

I: Pediatric Blood & Cancer, Bind 64, Nr. 2, 02.2017, s. 242-249.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Taskinen, M, Oskarsson, T, Levinsen, M, Bottai, M, Hellebostad, M, Jonsson, OG, Lähteenmäki, P, Schmiegelow, K & Heyman, M 2017, 'The effect of central nervous system involvement and irradiation in childhood acute lymphoblastic leukemia: Lessons from the NOPHO ALL-92 and ALL-2000 protocols', Pediatric Blood & Cancer, bind 64, nr. 2, s. 242-249. https://doi.org/10.1002/pbc.26191

APA

Taskinen, M., Oskarsson, T., Levinsen, M., Bottai, M., Hellebostad, M., Jonsson, O. G., Lähteenmäki, P., Schmiegelow, K., & Heyman, M. (2017). The effect of central nervous system involvement and irradiation in childhood acute lymphoblastic leukemia: Lessons from the NOPHO ALL-92 and ALL-2000 protocols. Pediatric Blood & Cancer, 64(2), 242-249. https://doi.org/10.1002/pbc.26191

Vancouver

Taskinen M, Oskarsson T, Levinsen M, Bottai M, Hellebostad M, Jonsson OG o.a. The effect of central nervous system involvement and irradiation in childhood acute lymphoblastic leukemia: Lessons from the NOPHO ALL-92 and ALL-2000 protocols. Pediatric Blood & Cancer. 2017 feb.;64(2):242-249. https://doi.org/10.1002/pbc.26191

Author

Taskinen, Mervi ; Oskarsson, Trausti ; Levinsen, Mette ; Bottai, Matteo ; Hellebostad, Marit ; Jonsson, Olafur Gisli ; Lähteenmäki, Päivi ; Schmiegelow, Kjeld ; Heyman, Mats. / The effect of central nervous system involvement and irradiation in childhood acute lymphoblastic leukemia : Lessons from the NOPHO ALL-92 and ALL-2000 protocols. I: Pediatric Blood & Cancer. 2017 ; Bind 64, Nr. 2. s. 242-249.

Bibtex

@article{8f736089ff154669b85ee5365558a3b2,
title = "The effect of central nervous system involvement and irradiation in childhood acute lymphoblastic leukemia: Lessons from the NOPHO ALL-92 and ALL-2000 protocols",
abstract = "BACKGROUND: Central nervous system irradiation (CNS-RT) has played a central role in the cure of acute lymphoblastic leukemia (ALL), but due to the risk of long-term toxicity, it is now considered a less-favorable method of CNS-directed therapy.PROCEDURES: Retrospectively, we estimated the effect of CNS involvement and CNS-RT on events and overall survival (OS) in 835 children treated for high-risk ALL in the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-92 and ALL-2000 trials.RESULTS: We did not observe a statistically significant difference in the OS or event-free survival (EFS) in patients with CNS involvement at diagnosis, but the risk of isolated CNS relapse was higher (hazard ratio [HR] 7.09, P < 0.001). CNS-RT was given to 169 of the 783 patients in first complete remission, of which 16 had CNS involvement at diagnosis. In general, CNS-RT improved EFS (HR 0.58, P < 0.05) but not OS (HR 0.69, P = n.s.). The adjusted HRs for all relapses, isolated bone marrow relapse, CNS-involving relapse, and isolated CNS relapse, were 0.47 (P < 0.01), 0.50 (P < 0.05), 0.34 (P < 0.01), and 0.12 (P < 0.01), respectively, in irradiated patients.CONCLUSIONS: CNS-RT was associated with an advantage in EFS by decreasing the risk of relapse but without improving OS.",
keywords = "Adolescent, Central Nervous System Neoplasms/etiology, Child, Child, Preschool, Combined Modality Therapy, Cranial Irradiation, Female, Follow-Up Studies, Humans, Infant, Male, Neoplasm Recurrence, Local/etiology, Neoplasm Staging, Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications, Prognosis, Retrospective Studies, Survival Rate",
author = "Mervi Taskinen and Trausti Oskarsson and Mette Levinsen and Matteo Bottai and Marit Hellebostad and Jonsson, {Olafur Gisli} and P{\"a}ivi L{\"a}hteenm{\"a}ki and Kjeld Schmiegelow and Mats Heyman",
note = "{\textcopyright} 2016 Wiley Periodicals, Inc.",
year = "2017",
month = feb,
doi = "10.1002/pbc.26191",
language = "English",
volume = "64",
pages = "242--249",
journal = "Pediatric Blood & Cancer",
issn = "1545-5009",
publisher = "JohnWiley & Sons, Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - The effect of central nervous system involvement and irradiation in childhood acute lymphoblastic leukemia

T2 - Lessons from the NOPHO ALL-92 and ALL-2000 protocols

AU - Taskinen, Mervi

AU - Oskarsson, Trausti

AU - Levinsen, Mette

AU - Bottai, Matteo

AU - Hellebostad, Marit

AU - Jonsson, Olafur Gisli

AU - Lähteenmäki, Päivi

AU - Schmiegelow, Kjeld

AU - Heyman, Mats

N1 - © 2016 Wiley Periodicals, Inc.

PY - 2017/2

Y1 - 2017/2

N2 - BACKGROUND: Central nervous system irradiation (CNS-RT) has played a central role in the cure of acute lymphoblastic leukemia (ALL), but due to the risk of long-term toxicity, it is now considered a less-favorable method of CNS-directed therapy.PROCEDURES: Retrospectively, we estimated the effect of CNS involvement and CNS-RT on events and overall survival (OS) in 835 children treated for high-risk ALL in the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-92 and ALL-2000 trials.RESULTS: We did not observe a statistically significant difference in the OS or event-free survival (EFS) in patients with CNS involvement at diagnosis, but the risk of isolated CNS relapse was higher (hazard ratio [HR] 7.09, P < 0.001). CNS-RT was given to 169 of the 783 patients in first complete remission, of which 16 had CNS involvement at diagnosis. In general, CNS-RT improved EFS (HR 0.58, P < 0.05) but not OS (HR 0.69, P = n.s.). The adjusted HRs for all relapses, isolated bone marrow relapse, CNS-involving relapse, and isolated CNS relapse, were 0.47 (P < 0.01), 0.50 (P < 0.05), 0.34 (P < 0.01), and 0.12 (P < 0.01), respectively, in irradiated patients.CONCLUSIONS: CNS-RT was associated with an advantage in EFS by decreasing the risk of relapse but without improving OS.

AB - BACKGROUND: Central nervous system irradiation (CNS-RT) has played a central role in the cure of acute lymphoblastic leukemia (ALL), but due to the risk of long-term toxicity, it is now considered a less-favorable method of CNS-directed therapy.PROCEDURES: Retrospectively, we estimated the effect of CNS involvement and CNS-RT on events and overall survival (OS) in 835 children treated for high-risk ALL in the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-92 and ALL-2000 trials.RESULTS: We did not observe a statistically significant difference in the OS or event-free survival (EFS) in patients with CNS involvement at diagnosis, but the risk of isolated CNS relapse was higher (hazard ratio [HR] 7.09, P < 0.001). CNS-RT was given to 169 of the 783 patients in first complete remission, of which 16 had CNS involvement at diagnosis. In general, CNS-RT improved EFS (HR 0.58, P < 0.05) but not OS (HR 0.69, P = n.s.). The adjusted HRs for all relapses, isolated bone marrow relapse, CNS-involving relapse, and isolated CNS relapse, were 0.47 (P < 0.01), 0.50 (P < 0.05), 0.34 (P < 0.01), and 0.12 (P < 0.01), respectively, in irradiated patients.CONCLUSIONS: CNS-RT was associated with an advantage in EFS by decreasing the risk of relapse but without improving OS.

KW - Adolescent

KW - Central Nervous System Neoplasms/etiology

KW - Child

KW - Child, Preschool

KW - Combined Modality Therapy

KW - Cranial Irradiation

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Infant

KW - Male

KW - Neoplasm Recurrence, Local/etiology

KW - Neoplasm Staging

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications

KW - Prognosis

KW - Retrospective Studies

KW - Survival Rate

U2 - 10.1002/pbc.26191

DO - 10.1002/pbc.26191

M3 - Journal article

C2 - 27748030

VL - 64

SP - 242

EP - 249

JO - Pediatric Blood & Cancer

JF - Pediatric Blood & Cancer

SN - 1545-5009

IS - 2

ER -

ID: 195153992